勃起功能障碍市场规模、份额和成长分析（按治疗类型、最终用户和地区）- 产业预测 2025-2032

2023 年全球勃起功能障碍市场规模价值 25 亿美元，预计将从 2024 年的 27.2 亿美元增长到 2032 年的 53.4 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.8%。

勃起功能障碍（ED），即无法达到或维持令人满意的勃起，是最常见的男性性健康问题，对身心健康有重大影响。这种疾病是由心理因素和生理因素造成的，生理因素包括高血压、肥胖、糖尿病和吸烟。随着 ED 盛行率的上升，医疗服务提供者和患者意识的提高，治疗方案的市场预计会扩大。然而，由于阴茎植入的高成本仍然是许多寻求有效解决方案的人面临的重大障碍，市场成长可能会受到阻碍。总体而言，ED 治疗市场有望成长，但定价仍然是关键挑战。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

勃起功能障碍市场规模（依治疗类型和复合年增长率） (2025-2032)

• 市场概况
• 药物
• Sildenafil
• 他达拉非
• 伐地那非
• 阿伐那非
• 其他的
• 阴茎植入
• 阴茎帮浦
• 其他的

勃起功能障碍市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院和诊所
• 门诊手术中心
• 药局
• 其他的

勃起功能障碍市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Pfizer（US）
• Eli Lilly and Company（US）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company（Japan）
• Mylan（US）（Now Viatris）
• Viatris（US）
• Teva Pharmaceutical Industries（Israel）
• Sun Pharmaceutical Industries（India）
• Cipla（India）
• Aurobindo Pharma（India）
• Lupin Limited（India）
• Dr. Reddy's Laboratories（India）
• Sandoz（Switzerland）
• Novartis（Switzerland）
• Abbott Laboratories（US）
• Sanofi（France）
• GlaxoSmithKline（GSK）（UK）
• Johnson & Johnson（US）
• Boston Scientific（US）
• Coloplast（Denmark）

结论和建议

Global Erectile Dysfunction Market size was valued at USD 2.5 billion in 2023 and is poised to grow from USD 2.72 billion in 2024 to USD 5.34 billion by 2032, growing at a CAGR of 8.8% during the forecast period (2025-2032).

Erectile dysfunction (ED), the inability to achieve or maintain a satisfactory erection, is the most common male sexual health issue and significantly impacts both physical and mental well-being. The condition arises from psychological and physiological factors, with the latter including high blood pressure, obesity, diabetes, and smoking. As the prevalence of ED rises, the market for treatment options is expected to expand, driven by increasing awareness among healthcare providers and patients. However, market growth may be hindered by the high costs associated with penile implants, which remain a significant barrier for many looking for effective solutions. Overall, the ED treatment market is poised for growth, but pricing remains a critical challenge.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Erectile Dysfunction market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Erectile Dysfunction Market Segments Analysis

Global Erectile Dysfunction Market is segmented by Treatment Type, End User and region. Based on Treatment Type, the market is segmented into Drugs, Sildenafil, Tadalafil, Vardenafil, Avanafil, Others, Penile Implants, Penis Pumps and Others. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgery Centers, Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Erectile Dysfunction Market

The Global Erectile Dysfunction market is significantly influenced by the increasing prevalence of diabetes, obesity, and cardiovascular diseases, all of which are linked to unhealthy lifestyle choices. As people age, these conditions contribute to erectile dysfunction (ED), with a particularly concerning trend among younger individuals in emerging countries where stressful lifestyles have led to a rise in fast food consumption, as well as drinking and smoking habits. These factors are undermining overall health and fitness, thereby heightening the risk of developing ED. Moreover, with the senior population on the rise, the number of individuals suffering from ED is expected to increase, further propelling the demand for ED medications globally throughout the forecast period.

Restraints in the Global Erectile Dysfunction Market

The global erectile dysfunction market faces significant restraints, particularly in low- and middle-income countries where sales represent a smaller fraction compared to developed and emerging economies. This limitation stems from several factors, including a general lack of awareness regarding available treatments, restricted purchasing power among potential consumers, and resistance to integrating these medications into daily routines. Additionally, the market's growth is hindered by the adverse side effects associated with erectile dysfunction drugs, such as headaches, nausea, flushing, nasal congestion, visual disturbances, dizziness, diarrhea, and skin rashes, all of which discourage potential users from pursuing treatment options.

Market Trends of the Global Erectile Dysfunction Market

The global erectile dysfunction market is experiencing notable growth, driven primarily by the enduring popularity of sildenafil, commonly known as Viagra. As a cornerstone treatment, sildenafil has demonstrated significant efficacy, with approximately two-thirds of users reporting improved erections, reinforcing its status as the first-line therapy for erectile dysfunction. The market's expansion is further supported by increasing awareness of sexual health, a growing aging population, and the rising incidence of conditions like diabetes and hypertension that contribute to erectile dysfunction. As a result, the erectile dysfunction market is poised for robust growth throughout the projection period, fueled by advancements in treatment options and a rising demand for effective therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Erectile Dysfunction Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Drugs
• Sildenafil
• Tadalafil
• Vardenafil
• Avanafil
• Others
• Penile Implants
• Penis Pumps
• Others

Global Erectile Dysfunction Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgery Centers
• Pharmacies
• Others

Global Erectile Dysfunction Market Size & CAGR (2025-2032)

• North America (Treatment Type, End User)
  • US
  • Canada
• Europe (Treatment Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (US) (Now Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coloplast (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations